Oxford, United Kingdom – 6th August 2025 – OMass Therapeutics (‘OMass’ or ‘the Company’), a biotechnology company identifying medicines against highly validated target ecosystems such as membrane proteins or intracellular complexes, today announces the appointment of Carol A. Schafer as non-executive Director and Chair of the Audit Committee.
Dr Simon Hirst, CEO and Founder of Sygnature Discovery has been awarded a prestigious honorary degree of Doctor of Science (D.Sc.) by The University of Nottingham.
Amsbio reports how the Sasaki Lab within the School of Veterinary Medicine at the University of Pennsylvania (USA) devised a protocol in which induced pluripotent stem cells (iPSCs) could be utilized to produce reconstituted human testes.
Since the original 2020 publication of their groundbreaking research, Dr Kotaro Sasaki’s team has made significant progress in reconstituting human testis-like tissue from iPSCs.
The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has approved elinzanetant (branded as Lynkuet™) for the treatment of moderate to severe hot flushes and night sweats associated with menopause. These symptoms, also known as vasomotor symptoms, affect a significant proportion of women and can have a considerable impact on quality of life.
The Head of Research Data & Technology is fundamental to the continuing success of the NIHR BioResource. As part of the Senior Management Team (SMT) the role is actively involved in overall strategy and planning, along with providing expert advice to the SMT, Oversight Committees and the Director of the NIHR BioResource.
Research conducted by Pioneer Group in collaboration with Beauhurst into the UK life sciences landscape reveals a growing trend of investment into more mature companies. The report also highlights a persistent regional imbalance, with ‘Golden Triangle’ university spinouts attracting significantly more funding than those elsewhere.
Join Cambridge Network and Marks & Clerk for an event exploring the legal aspects of harnessing the potential of artificial intelligence to drive innovation and efficiency in your business. From automating workflows to generating new content, AI is transforming industries. We’ll explore what to look out for in AI licence terms, how to limit your liability, and the critical question: will you actually own the output your AI creates?
How to leverage CRM to improve sales performance to get you out of a world of sales pain.
Does this sound familiar to you?
This session will be led by Mike Basketter, Commercial Director at CRM Insights.
During the session you will discover:
Cambridge, UK – 4 August 2025: Microbiotica, a clinical-stage biopharma company developing a pipeline of oral precision microbiome medicines called live biotherapeutic products (LBPs), announces that patient recruitment is complete in its Phase 1b First-in-Human trial, COMPOSER-1, of MB310 in ulcerative colitis (UC) patients.
This international trial has recruited 29 adult patients at clinical centres in the UK, Austria, Bulgaria, Poland and Spain. Initial results are expected by the end of 2025.
